pVITRO1-Trastuzumab-IgG4/κ Citations (2)

Originally described in: A tool kit for rapid cloning and expression of recombinant antibodies.
Dodev TS, Karagiannis P, Gilbert AE, Josephs DH, Bowen H, James LK, Bax HJ, Beavil R, Pang MO, Gould HJ, Karagiannis SN, Beavil AJ Sci Rep. 2014 Jul 30;4:5885. doi: 10.1038/srep05885. PubMed Journal

---

Articles Citing pVITRO1-Trastuzumab-IgG4/κ

Articles
IgG4 Valency Modulates the Pathogenicity of Anti-Neurofascin-155 IgG4 in Autoimmune Nodopathy. Jentzer A, Attal A, Roue C, Raymond J, Lleixa C, Illa I, Querol L, Taieb G, Devaux J. Neurol Neuroimmunol Neuroinflamm. 2022 Aug 10;9(5):e200014. doi: 10.1212/NXI.0000000000200014. Print 2022 Sep. PubMed
The hinge-engineered IgG1-IgG3 hybrid subclass IgGh(47) potently enhances Fc-mediated function of anti-streptococcal and SARS-CoV-2 antibodies. Izadi A, Karami Y, Bratanis E, Wrighton S, Khakzad H, Nyblom M, Olofsson B, Happonen L, Tang D, Sundwall M, Godzwon M, Chao Y, Toledo AG, Schmidt T, Ohlin M, Nilges M, Malmstrom J, Bahnan W, Shannon O, Malmstrom L, Nordenfelt P. Nat Commun. 2024 Apr 27;15(1):3600. doi: 10.1038/s41467-024-47928-8. PubMed

If you have published an article using this material, please email us at to have your article added to this page.